NEW YORK (Thomson Financial) - Akorn-Strides LLC - a joint venture of Akorn Inc. and Strides Arcolab Ltd. - Wednesday said the Food and Drug Administration has approved its abbreviated new drug application for flumazenil injection USP packaged in five milliliter and 10 milliliter multiple dose vials.

Flumazenil is indicated for the complete or partial reversal of the sedative effects of benzodiazepines.

Akorn shares closed at $4.21 on Tuesday. Christie Rizk cr/pc

COPYRIGHT

Copyright Thomson Financial News Limited 2007. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.